Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| 1,4-Bis(4-nitrophenyl)piperazine | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 1,4-Bis(4-nitrophenyl)piperazine; 16264-05-4; Piperazine, 1,4-bis(4-nitrophenyl)-EINECS 240-371-8UNII-P6TE7B2EYY. CAS No. 16264-05-4. Pack Sizes: 100 mg. Product ID: B1476-166965. Molecular formula: C16H16N4O4. Mole weight: 328.328. Custom synthesis is available. Send your inquiries for more information. |  London |
| 5-bromo-4-chloro-N-cyclopentylpyrimidin-2-amine | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 5-Bromo-4-chloro-N-cyclopentylpyrimidin-2-amine; 1823404-28-9; CS-0011349; D87404; 5-?Bromo-?4-?chloro-?N-?cyclopentylpyrimidin?-?2-?amine. CAS No. 1823404-28-9. Pack Sizes: 100 mg. Product ID: B1476-284923. Molecular formula: C9H11BrClN3. Mole weight: 276.56. Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Bromo-8-cyclopentyl-2-[[5-(4-Boc-1-piperazinyl)-2-pyridyl]amino]-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 4-[6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxo-2-pyrido[2,3-d]pyrimidinyl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid tert-butyl ester; tert-butyl 4-[6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylate. CAS No. 571188-82-4. Pack Sizes: 100 mg. Product ID: B1476-282703. Molecular formula: C27H34BrN7O3. Mole weight: 584.51. Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl-6-Bromo Palbociclib | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 6-Bromo-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; Pyrido-[2,3-d]-pyrimidin-7-one 41. CAS No. 851067-56-6. Pack Sizes: 100 mg. Product ID: B1476-283285. Molecular formula: C22H26BrN7O. Mole weight: 484.402. Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl-6-Bromo Palbociclib Hydrochloride | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 6-bromo-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride. CAS No. 850918-83-1. Pack Sizes: 100 mg. Product ID: B1476-284929. Molecular formula: C22H27ClBrN7O. Mole weight: 520.86. Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl Palbociclib | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: Pyrido[2,3-d]pyriMidin-7(8H)-one, 8-cyclopentyl-5-Methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]aMino]-; Pyrido-[2,3-d]-pyrimidin-7-one 38. CAS No. 571190-22-2. Pack Sizes: 100 mg. Product ID: B1476-478511. Molecular formula: C22H27N7O. Mole weight: 405.506. Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl Palbociclib Hydrochloride | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride. CAS No. 571189-66-7. Pack Sizes: 100 mg. Product ID: B1476-284928. Molecular formula: C22H28ClN7O. Mole weight: 441.96. Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib | Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Alternative Names: LY-2835219; LY 2835219; LY2835219; Verzenio; N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine. CAS No. 1231929-97-7. Pack Sizes: 100 mg. Product ID: B0084-462724. Molecular formula: C27H32F2N8. Mole weight: 506.61. Custom synthesis is available. Send your inquiries for more information. | London |
| Alsterpaullone | Alsterpaullone is a potent glycogen synthase kinase-3 inhibitor and a potential therapeutic agent for the treatment of Parkinson disease. Alsterpaullone is also known as 9-Nitropaullone and NSC 705701, which is a derivative of kenpaullone and an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Alsterpaullone induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Alsterpaullone is a derivative of kenpaullone with slightly improved potency over kenpaullone, alsterpaullone selectively inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and GSK3α/β with IC50 values of 35, 15, 200, 40, and 4 nM, respectively. Group: Pharmaceutical. Alternative Names: 9-Nitropaullone; NSC 705701; 7,12-Dihydro-9-nitro-indolo[3,2-d][1]benzazepin-6(5H)-one. CAS No. 237430-03-4. Pack Sizes: 50 mg. Product ID: B2693-103248. Molecular formula: C16H11N3O3. Mole weight: 293.3. Custom synthesis is available. Send your inquiries for more information. | London |
| Entinostat | Entinostat is a histone deacetylase (HDAC) inhibitor displaying antiproliferative and antineoplastic effects. Entinostat induces cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1), which slows cell growth, differentiation, and tumor development in vivo. Entinostat is potentially used as an antitumor drug in combination with other drugs like adriamycin, PARP inhibitors and Hsp90 inhibitors. Uses: Histone deacetylase inhibitors. Group: Pharmaceutical. Alternative Names: MS275; MS-275; MS 2275; SNDX275; SNDX-275; SNDX 275; Entinostat; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate. CAS No. 209783-80-2. Pack Sizes: 500 mg. Product ID: B0084-062759. Molecular formula: C21H20N4O3. Mole weight: 376.416. Custom synthesis is available. Send your inquiries for more information. | London |
| Ganoderiol F | Lansiumarin C is a natural coumarin found in the branches of Clausena lansium. and found to induce senescence of cancer cell lines, it induces growth arrest of cancer cell lines HepG2, Huh7 and K562; activation of the mitogen-activated protein kinase EKR and up-regulation of cyclin-dependent kinase inhibitor p16 were found in early stages of Ganoderiol F treatment and were presumed to cause cell-cycle arrest and trigger premature senescence of HepG2 cells; suggests that the growth-arrest and senescence induction capability on cancer cells suggest anticancer potential of Ganoderiol F. It could be developed further as both anti-HIV and antimalaria.In Compared to plasmepsin I, ganoderiol-F is higher towards HIV-1 protease. Uses: Anti-inflammatory; anti-hiv. Group: Pharmaceutical. Alternative Names: 26,27-Dihydroxylanosta-7,9(11),24-trien-3-one. CAS No. 114567-47-4. Pack Sizes: 1 mg. Product ID: NP6829. Molecular formula: C30H46O3. Mole weight: 454.7. Custom synthesis is available. Send your inquiries for more information. | London |
| ICEC-0942 | ICEC-0942 is a small-molecule cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. Preclinical study in Acute Myeloid Leukaemia (AML) models shows that ICEC-0942 effectively inhibits the proliferation of several AML cell lines and patient derived AML cells in vitro (IC50 = 0.15-2.6 μM). Uses: Anticancer drug. Group: Pharmaceutical. Alternative Names: CT7001; CT 7001; CT-7001; ICEC0942; ICEC0 942; ICEC0-942. CAS No. 1805833-75-3. Pack Sizes: 10 mg. Product ID: B0084-008621. Molecular formula: C22H30N6O. Mole weight: 394.52. Custom synthesis is available. Send your inquiries for more information. | London |
| Indirubin | Indirubin is an inhibitor of GSK-3β and cyclin-dependent kinases (CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, CDK5/p35). Also, Indirubin is a specific Aryl Hydrocarbon receptor (AHR) ligand. Uses: Antibiotics, antineoplastic. Group: Pharmaceutical. Alternative Names: Indirubin; C.I. 73200, Couroupitine B, Indigo red, Indigopurpurin, NSC 105327; NSC-105327; NSC105327; Indigopurpurin; Couroupitine B; [2,3'-Biindolinylidene]-2',3-dione; 3-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-2H-indol-2-one. CAS No. 479-41-4. Pack Sizes: 200 mg. Product ID: NP0564. Molecular formula: C16H10N2O2. Mole weight: 262.268. Custom synthesis is available. Send your inquiries for more information. | London |
| LEE011 succinate | LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific inhibitor) or BYL719 (a PIK3CA specific inhibitor) leads to robust anti-tumor activity in melanoma and breast cancer tumor models. Group: Pharmaceutical. Alternative Names: Ribociclib succinate; LEE 011 succinate; LEE-011 succinate. CAS No. 1374639-75-4. Pack Sizes: 1 g. Product ID: B2693-463203. Molecular formula: C27H36N8O5. Mole weight: 552.63. Custom synthesis is available. Send your inquiries for more information. | London |
| Milciclib | Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types. Group: Pharmaceutical. Alternative Names: PHA-848125; PHA848125; PHA 848125; PHA-848125AC; PHA 848125AC; PHA848125AC. CAS No. 802539-81-7. Pack Sizes: 5 mg. Product ID: B0084-459709. Molecular formula: C25H32N8O. Mole weight: 460.57. Custom synthesis is available. Send your inquiries for more information. | London |
| MK-1775 | MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Group: Pharmaceutical. Alternative Names: MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one. CAS No. 955365-80-7. Pack Sizes: 300 mg. Product ID: B0084-157422. Molecular formula: C27H32N8O2. Mole weight: 500.607. Custom synthesis is available. Send your inquiries for more information. | London |
| Pabociclib Impurity B | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: tert-butyl 4-[6-[(6-acetyl-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylate. CAS No. 1651214-74-2. Pack Sizes: 100 mg. Product ID: B1476-478509. Molecular formula: C29H37N7O4. Mole weight: 547.66. Custom synthesis is available. Send your inquiries for more information. | London |
| Pabociclib Impurity B Hydrochloride | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: tert-butyl 4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate hydrochloride. CAS No. 1883672-48-7. Pack Sizes: 100 mg. Product ID: B1476-284924. Molecular formula: C29H38ClN7O4. Mole weight: 584.11. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib | Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. Group: Pharmaceutical. Alternative Names: PD 0332991; PD0332991; PD-0332991; Ibrance; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one. CAS No. 571190-30-2. Pack Sizes: 5 g. Product ID: BBF-05853. Molecular formula: C24H29N7O2. Mole weight: 447.53. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib HCl | Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation. PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50=0.011 μmol/L) and Cdk6 (IC50=0.016 μmol/L), having no activity against a panel of 36 additional protein kinases. Group: Pharmaceutical. Alternative Names: PD 0332991; PD 332991; PD0332991; PD-0332991; Palbociclib hydrochloride. CAS No. 827022-32-2. Pack Sizes: 1 g. Product ID: B2693-462758. Molecular formula: C24H29N7O2.HCl. Mole weight: 483.99. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib Impurity 10 | Palbociclib Impurity 10 is an impurity of Palbociclib, which is a selective cyclin-dependent kinases CDK4 and CDK6 inhibitor used for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 1-Piperazinecarboxylic acid, 4,4'-[(8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidine-2,6-diyl)bis(imino-2,5-pyridinediyl)]bis-, 1,1'-bis(1,1-dimethylethyl) ester; 1,1'-Bis(1,1-dimethylethyl) 4,4'-[(8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidine-2,6-diyl)bis(imino-2,5-pyridinediyl)]bis[1-piperazinecarboxylate]; Bis(2-methyl-2-propanyl) 4,4'-[(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-2,6-diyl)bis(imino-2,5-pyridinediyl)]di(1-piperazinecarboxylate). CAS No. 2206135-30-8. Pack Sizes: 2 mg. Product ID: B2694-338793. Molecular formula: C41H55N11O5. Mole weight: 781.94. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib Impurity 2 | Palbociclib Impurity 2 is an impurity of Palbociclib, which is a selective cyclin-dependent kinases CDK4 and CDK6 inhibitor used for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: Desoxo-palbociclib; Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-cyclopentyl-6-ethenyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-; 8-Cyclopentyl-6-ethenyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; Palbociclib Impurity D. CAS No. 2204863-06-7. Pack Sizes: 5 mg. Product ID: B2694-338794. Molecular formula: C24H29N7O. Mole weight: 431.53. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib Impurity 4 | An impurity of Palbociclib which is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor to treat ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: Pyrido[2,?3-d]?pyrimidin-7(8H)?-one, 8-cyclopentyl-6-(1-hydroxyethyl)?-5-methyl-2-[[5-(1-piperazinyl)?-2-pyridinyl]?amino]?-. CAS No. 1376615-91-6. Pack Sizes: 10 mg. Product ID: B2694-478516. Molecular formula: C24H31N7O2. Mole weight: 449.56. Custom synthesis is available. Send your inquiries for more information. | London |
| Ribociclib | Ribociclib, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. Group: Pharmaceutical. Alternative Names: LEE011; LEE 011; LEE-011; Kisqali. CAS No. 1211441-98-3. Pack Sizes: 200 mg. Product ID: B0084-462559. Molecular formula: C23H30N8O. Mole weight: 434.55. Custom synthesis is available. Send your inquiries for more information. | London |
| Seliciclib | Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Mcl-1 belongs to the Bcl-2 family of antiapoptotic proteins and is a protein crucial to the survival of a range of tumor cell types. Group: Pharmaceutical. Alternative Names: R-roscovitine; Roscovitin; Roscovitine; CYC202; CYC202; CYC 202; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol. CAS No. 186692-46-6. Pack Sizes: 100 mg. Product ID: B1370-086385. Molecular formula: C19H26N6O. Mole weight: 354.44. Custom synthesis is available. Send your inquiries for more information. | London |
| Tert-butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 4-[6-[6-(1-butoxy-vinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester. CAS No. 866084-31-3. Pack Sizes: 100 mg. Product ID: B1476-283415. Molecular formula: C33H45N7O4. Mole weight: 603.768. Custom synthesis is available. Send your inquiries for more information. | London |
| tert-butyl 4-(6-((8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 571189-65-6. Pack Sizes: 100 mg. Product ID: B1476-284927. Molecular formula: C27H35N7O3. Mole weight: 505.61. Custom synthesis is available. Send your inquiries for more information. | London |
| THZ1 | THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cyclin-dependent kinases (CDKs) are involved in temporal control of the cell cycle and transcription and play central roles in cancer development and metastasis. Group: Pharmaceutical. Alternative Names: HY-80013; THZ-1; HY 80013; THZ 1; HY80013; THZ1; N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide. CAS No. 1604810-83-4. Pack Sizes: 300 mg. Product ID: B0084-462601. Molecular formula: C31H28ClN7O2. Mole weight: 566.062. Custom synthesis is available. Send your inquiries for more information. | London |
| Tri-O-tolylphosphine oxide | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. Alternative Names: 1-bis(2-methylphenyl)phosphoryl-2-methylbenzene; Phosphine oxide, tri-o-tolyl-; Phosphine oxide, tris(2-methylphenyl)-. CAS No. 6163-63-9. Pack Sizes: 100 mg. Product ID: B1476-318503. Molecular formula: C21H21OP. Mole weight: 320.372. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
